That being said, to our knowledge, our study reports the first evidence of a successful combination therapy of ALK and STAT3 inhibitors against an EML4-ALK fusion-positive NSCLC in vivo model, which is potentially beneficial information for this patient population. The gene discussed is EML4; the disease is non-small cell lung carcinoma.